A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Pfizer

Status: Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: Lorlatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06678555

B7461048

NCT06678555 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled.

This study is seeking participants who:

• have lung cancer that could not be controlled.
• have a type of gene called a ROS proto-oncogene 1. A gene is a part of your DNA that has instructions for making things your body needs to work.
• have received at least 1 treatment before.

All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take lorlatinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.

Enrollment: 35 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients are aged 18 years or older on index date
2. Patients have confirmed diagnosis of ROS1-positive NSCLC
3. Patients have received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023

Exclusion criteria

1. Patients participated in any clinical trials using lorlatinib during the observation period.

Trial design

35 participants in 1 patient group

Lorlatinib

Description:

Patients with ROS1(+) advanced/metastatic NSCLC had been treated with lorlatinib.

Treatment:

Drug: Lorlatinib